DK0889969T3 - Rekombinante adenovirale til genterapi af humane tumorer - Google Patents

Rekombinante adenovirale til genterapi af humane tumorer

Info

Publication number
DK0889969T3
DK0889969T3 DK97914375T DK97914375T DK0889969T3 DK 0889969 T3 DK0889969 T3 DK 0889969T3 DK 97914375 T DK97914375 T DK 97914375T DK 97914375 T DK97914375 T DK 97914375T DK 0889969 T3 DK0889969 T3 DK 0889969T3
Authority
DK
Denmark
Prior art keywords
gene therapy
disclosed
human tumors
recombinant adenoviral
treating
Prior art date
Application number
DK97914375T
Other languages
English (en)
Inventor
Michel Perricaudet
Falleur Boon
Marie-Therese Duffour
Hedi Haddada
Christophe Lurquin
Catherine Uyttenhoveghesquiere
Guy Warnier
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Application granted granted Critical
Publication of DK0889969T3 publication Critical patent/DK0889969T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97914375T 1996-03-14 1997-03-12 Rekombinante adenovirale til genterapi af humane tumorer DK0889969T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants

Publications (1)

Publication Number Publication Date
DK0889969T3 true DK0889969T3 (da) 2006-03-27

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97914375T DK0889969T3 (da) 1996-03-14 1997-03-12 Rekombinante adenovirale til genterapi af humane tumorer

Country Status (19)

Country Link
US (1) US20030082150A1 (da)
EP (1) EP0889969B1 (da)
JP (1) JP2000507229A (da)
KR (1) KR19990087718A (da)
CN (1) CN1218512A (da)
AT (1) ATE309382T1 (da)
AU (1) AU732288B2 (da)
BR (1) BR9707994A (da)
CA (1) CA2248612A1 (da)
CZ (1) CZ295967B6 (da)
DE (1) DE69734574T2 (da)
DK (1) DK0889969T3 (da)
ES (1) ES2252779T3 (da)
FR (1) FR2746110B1 (da)
HU (1) HUP9902150A3 (da)
IL (1) IL126152A0 (da)
NO (1) NO984052D0 (da)
SK (1) SK124698A3 (da)
WO (1) WO1997034009A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015638A2 (en) * 1996-10-07 1998-04-16 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
AU1013601A (en) 1999-10-22 2001-05-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DK1282702T3 (da) * 2000-05-10 2007-04-02 Sanofi Pasteur Ltd Immunogene polypeptider, som er kodet af KAGE-minigener, og anvendelser deraf
AU2002258631B2 (en) * 2001-03-27 2007-05-17 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
US7786278B2 (en) 2002-04-09 2010-08-31 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
AU2003228792A1 (en) * 2002-04-30 2003-11-17 Avior Therapeutics, Inc. Adenovirus vectors for immunotherapy
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CN101124327A (zh) * 2003-10-08 2008-02-13 圣诺菲·帕斯图尔公司 经修饰的cea/b7载体
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
DE69435108D1 (de) * 1993-07-13 2008-08-14 Centelion Defekte adenovirus-vektoren und deren verwendung in der gentherapie

Also Published As

Publication number Publication date
FR2746110B1 (fr) 1998-04-17
ES2252779T3 (es) 2006-05-16
US20030082150A1 (en) 2003-05-01
CN1218512A (zh) 1999-06-02
ATE309382T1 (de) 2005-11-15
AU2164197A (en) 1997-10-01
BR9707994A (pt) 1999-07-27
IL126152A0 (en) 1999-05-09
JP2000507229A (ja) 2000-06-13
CZ295967B6 (cs) 2005-12-14
AU732288B2 (en) 2001-04-12
NO984052L (no) 1998-09-03
HUP9902150A3 (en) 2000-12-28
EP0889969B1 (fr) 2005-11-09
SK124698A3 (en) 1999-05-07
HUP9902150A2 (hu) 1999-11-29
EP0889969A1 (fr) 1999-01-13
CA2248612A1 (fr) 1997-09-18
FR2746110A1 (fr) 1997-09-19
WO1997034009A1 (fr) 1997-09-18
CZ291598A3 (cs) 1998-12-16
DE69734574D1 (de) 2005-12-15
DE69734574T2 (de) 2006-07-13
NO984052D0 (no) 1998-09-03
KR19990087718A (ko) 1999-12-27

Similar Documents

Publication Publication Date Title
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
DK0889969T3 (da) Rekombinante adenovirale til genterapi af humane tumorer
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
ATE282434T1 (de) Eine zusammensetzung enthaltend eine detergenz und einen ein tumorsuppressorgen kodierenden, adenoviralen vektor
BR9908823A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
WO1998037093A3 (en) Compounds for immunotherapy of prostate cancer and methods for their use
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
NO953684L (no) Fremgangsmåte for fremstilling av kreftvaksiner
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
IT1298487B1 (it) Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
AR004341A1 (es) Vacunas contra tumores y procedimiento para su produccion.
MY141459A (en) Recombinant anti-idiotypic antibodies
DE60238044D1 (de) Tumortherapie mit vektoren auf sindbis virus-basis
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
DK1007717T3 (da) Metoder og sammensætninger til cancerterapi under anvendelse af gener, der koder for interferon-beta
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
UY26170A1 (es) Antigeno (c42) asociados a tumores
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
ATE291620T1 (de) Mammakarzinom-assoziiertes gen